Phosphodiesterase 11A (PDE11A) and genetic predisposition to adrenocortical tumors

Clinical Cancer Research

Volumn 14, Issue 12, 2008, Pages 4016-4024

  Libé, Rossella ^a,b,c,d,e   Fratticci, Amato ^a,b,c,d   Coste, Joel ^b   Tissier, Frédérique ^a,b,c,d,f   Horvath, Anelia ^g   Ragazzon, Bruno ^a,b,c,d   Rene Corail, Fernande ^a,b,c,d   Groussin, Lionel ^a,b,c,d,e   Bertagna, Xavier ^e   Raffin Sanson, Marie Laure ^a,b,c,d,h   Stratakis, Constantine A ^g   Bertherat, Jerome ^a,b,c,d,e,i  

^a INSERM   (France)

^b Lnstitut Cochin ^*  (France)

^c INSTITUT COCHIN   (France)

^d UNIVERSITÉ PARIS DESCARTES   (France)

^e Reference Center for Rare Epilepsies   (France)

^f Department of Biostatistics ^*  (France)

^g EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH AND HUMAN DEVELOPMENT   (United States)

^h LABORATOIRE DES SCIENCES DU CLIMAT ET DE L ENVIRONNEMENT   (France)

ⁱ HÔPITAL AMBROISE PARÉ   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ARGININE; CYCLIC AMP; PDE11A PROTEIN, HUMAN; PHOSPHODIESTERASE;

ADRENAL CORTEX ADENOMA; ADRENAL CORTEX CARCINOMA; ADRENAL CORTEX TUMOR; ADULT; ALLELE; ARTICLE; CONTROLLED STUDY; CUSHING SYNDROME; EXON; FEMALE; GENE; GENE SEQUENCE; GENETIC PREDISPOSITION; HUMAN; HUMAN CELL; INTRON; MALE; MISSENSE MUTATION; PDE11A GENE; PRIORITY JOURNAL; SEQUENCE ANALYSIS; CASE CONTROL STUDY; GENETICS; METABOLISM; MIDDLE AGED; NUCLEOTIDE SEQUENCE; PRECANCER; SINGLE NUCLEOTIDE POLYMORPHISM;

ADRENAL CORTEX NEOPLASMS; ADRENOCORTICAL ADENOMA; ADULT; BASE SEQUENCE; CASE-CONTROL STUDIES; DNA MUTATIONAL ANALYSIS; FEMALE; GENETIC PREDISPOSITION TO DISEASE; HUMANS; MALE; MIDDLE AGED; MUTATION, MISSENSE; PHOSPHORIC DIESTER HYDROLASES; POLYMORPHISM, SINGLE NUCLEOTIDE; PRECANCEROUS CONDITIONS;

EID: 52449114622     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-08-0106     Document Type: Article

References (36)

1. Sidhu S, Sywak M, Robinson B, Delbridge L Adrenocortical cancer: recent clinical and molecular advances. Curr Opin Oncol 2004;16:13-8.
2. Libe R, BertheratJ. Molecular genetics of adrenocortical tumours, from familial to sporadic diseases. Eur J Endocrinol 2005;153:477-87.
3. Beuschlein F, Reincke M. Adrenocortical tumorigenesis. Ann N YAcad Sci 2006;1088:319-34.
4. Libe R, Fratticci A, Bertherat J. Adrenocortical cancer: pathophysiology and clinical management. Endocr Relat Cancer 2007:14:13-28.
5. Stratakis CA, Boikos SA. Genetics of adrenal tumors
6. associated with Cushing's syndrome: a new classification for bilateral adrenocortical hyperplasias. Nat Clin Pract Endocrinol Metab 2007;3:748-57.
7. Groussin L, Jullian E. Perlemoine K, et al. Mutations of the PRKAR1A gene in Cushing's syndrome due to sporadic primary pigmented nodular adrenocortical disease. J Clin Endocrinol Metab 2002;87:4324-9.
8. Swords FM, Baig A, Malchoff DM, et al. Impaired desensitization of a mutant adrenocorticotropin receptor associated with apparent constitutive activity. Mol Endocrinol 2002;16:2746-53.
9. Weinstein LS, Shenker A, Gejman PV, Merino MJ,
10. Friedman E, Spiegel AM. Activating mutations of the stimulatory G protein in the McCune-Albright syndrome. N Engl J Med 1991;325:1688-95.
11. Kirschner LS, Carney JA, Pack SD. et al. Mutations of the gene encoding the protein kinase A type l-α regulatory subunit in patients with the Carney complex. Nat Genet 2000;26:89-92.
12. Groussin L, Kirschner LS, Vincent-Dejean C, et al. Molecular analysis of the cyclic AMP-dependent protein kinase A (PKA) regulatory subunit 1A (PRKAR1A) gene in patients with Carney complex and primary pigmented nodular adrenocortical disease (PPNAD) reveals novel mutations and clues for pathophysiology: augmented PKA signaling is associated with adrenal tumorigenesis in PPNAD. Am J Hum Genet 2002.71:1433-42.
13. Bertherat J, Groussin L, Sandrini F, et al. Molecular and functional analysis of PRKAR1A and its locus (17q22-24) in sporadic adrenocortical tumors:17q losses, somatic mutations, and protein kinase A expression and activity. Cancer Res 2003;63:5308-19.
14. Horvath A, Boikos S, Giatzakis C, et al. A genome-wide scan identifies mutations in the gene encoding phosphodiesterase 11A4 (PDE11A) in individuals with adrenocortical hyperplasia. Nat Genet 2006;38:794-800.
15. Horvath A, Giatzakis C, Robinson-White A, et al. Adrenal hyperplasia and adenomas are associated with inhibition of phosphodiesterase 11A in carriers of PDE11A sequence variants that are frequent in the population. Cancer Res 2006;66:11571 -5.
16. Gicquel C, Bertagna X, Gaston V, et al. Molecular markers and long-term recurrences in a large cohort of patients with sporadic adrenocortical tumors. Cancer Res 2001;61:6762-7
17. Libe R, Groussin L, Tissier F, et al. Somatic TP53 mutations are relatively rare among adrenocortical cancers with the frequent 17p13 loss of heterozygosity. Clin Cancer Res 2007;13:844-50.
18. Tissier F, Cavard C, Groussin L, et al. Mutations of β-catenin in adrenocortical tumors: activation of the Wnt signaling pathway is a frequent event in both benign and malignant adrenocortical tumors. Cancer Res 2005;65:7622-7.
19. Cazabat L, Libe R, Perlemoine K, et al. Germline inactivating mutations of the aryl hydrocarbon receptor-interacting protein gene in a large cohort of sporadic acromegaly: mutations are found in a subset of young patients with macroadenomas. Eur J Endocrinol 2007:157:1 -8.
20. Tissier F, Louvel A, Grabar S. et al. Cyclin E correlates with malignancy and adverse prognosis in adrenocortical tumors. Eur J Endocrinol 2004:150: 809-17.
21. Pharoah PD, Dunning AM, Ponder BA, Easton DF. Association studies for finding cancer-susceptibility genetic variants. Nat Rev Cancer 2004;4:850-60
22. Pharoah PD, Tyrer J, Dunning AM, Easton DF, Ponder BA. Association between common variation in 120 candidate genes and breast cancer risk PLoS Genet 2007;3:e42.
23. Meijers-Heijboer H, van den Ouweland A, Klijn J, et al. Low-penetrance susceptibility to breast cancer due to CHEK2(*)1100delC in noncarriers of BRCA1 or BRCA2 mutations. Nat Genet 2002;31:55-9.
24. Antoniou AC, Easton DF. Polygenic inheritance of breast cancer: implications for design of association studies. Genet Epidemiol 2003,25:190-202.
25. Menniti FS, Faraci WS, Schmidt CJ. Phosphodiesterases in the CNS: targets for drug development. Nat Rev Drug Discov 2006;5:660-70.
26. Wong ML, Whelan F, Deloukas P, et al. Phosphodiesterase genes are associated with susceptibility to major depression and antidepressant treatment response. Proc Natl Acad Sci U S A 2006:103:15124-9
27. Kryukov GV, Pennacchio LA, Sunyaev SR. Most rare missense alleles are deleterious in humans: implications for complex disease and association studies Am J Hum Genet 2007;80:727-39.
28. Calin GA, Trapasso F, Shimizu M, et al. Familial cancer associated with a polymorphism in ARLTS1 N Engl J Med 2005;352:1667-76
29. Scherer D, Bermejo JL, Rudnai P, et al MC1R variants associated susceptibility to basal cell carcinoma of skin: interaction with host factors and XRCC3 polymorphism. Int J Cancer 2008:122:1787-93.
30. NackleyAG, Shabalina SA, Tchivileva IE, et al Human catechol-O- methyltransferase haplotypes modulate protein expression by altering mRNA secondary structure. Science 2006:314:1930-3.
31. Stratigos AJ, Dimisianos G. Nikolaou V. et al. Mela-nocortin receptor-1 gene polymorphisms and the risk of cutaneous melanoma in a low-risk southern European population. J Invest Dermatol 2006:126 1842-9
32. Papadakis EN, Dokianakis DN, Spandidos DA p53 codon 72 polymorphism as a risk factor in the development of breast cancer. Mol Cell Biol Res Commun 2000:3:389-92.
33. Koushik A. Piatt RW, Franco EL p53 codon 72 polymorphism and cervical neoplasia: a meta-analysis review. Cancer Epidemiol Biomarkers Prev 2004:13 11 -22.
34. Zhang X, Miao X, Guo Y, et al. Genetic polymorphisms in cell cycle regulatory genes MDM2 and TP53 are associated with susceptibility to lung cancer. Hum Mutat 2006:27:110-7
35. Boersma BJ, HoweTM, Goodman JE. et al Association of breast cancer outcome with status of p53 and MDM2 SNP309. J Natl Cancer Inst 2006:98:911 -9
36. ToyamaT, Zhang Z, Nishio M. et al. Association of TP53 codon 72 polymorphism and the outcome of adjuvant therapy in breast cancer patients Breast Cancer Res 2007;9:R34.